Kenya to pilot new malaria vaccine

Kenya is set to be part of a groundbreaking effort to pilot a new malaria vaccine, alongside Ghana and Malawi, in collaboration with the World Health Organization. The vaccination program aims to reach over 750,000 children and, if successful, could prevent an estimated 6.7 million new clinical cases in Kenya while reducing the annual mortality rate by 4,000. Dr. Rebecca Kiptui, from the Kenyan National Malaria Control Program at the Ministry of Health, provided insights into this crucial initiative in a recent interview on CNBC Africa. Dr. Kiptui expressed the significance of this milestone, emphasizing that the journey towards a malaria vaccine has been a lengthy one, spanning over 30 years of research. The vaccine under consideration, known as RTSS, represents the furthest advancement in malaria vaccine development to date. In addressing concerns about the safety and efficacy of the vaccine, Dr. Kiptui reassured that rigorous safety protocols are being followed. The European Medical Agency has provided a positive scientific opinion on the vaccine's safety profile. The upcoming pilot program will focus on monitoring and studying the safety aspects of RTSS, with regulatory authorities overseeing pharmacovigilance to track any adverse effects. Funding for the initial phase of the pilot program has been secured through contributions from various organizations. Gavi will provide approximately $27.5 million, the Global Fund will offer $15 million, and UNITAID will contribute around $9.6 million towards the trial. The government's involvement in Kenya's participation is vital, as the health system infrastructure is key to implementing the vaccine within routine immunization schedules. The regulatory authorities will also play a crucial role in ensuring proper registration and monitoring of the vaccine's safety. Notably, RTSS will complement existing malaria preventive interventions rather than replace them. Children receiving the vaccine will still be advised to use insecticide-treated nets and indoor residual spraying as part of comprehensive malaria control efforts. The selection of Kenya, along with Malawi and Ghana, was based on criteria including high coverage of preventive measures like bed nets, well-functioning malaria control and immunization programs. The choice of these countries reflects their readiness to conduct the pilot program effectively. Dr. Kiptui provided insights into the malaria situation in Kenya, highlighting regional variations in disease burden. While progress has been made in reducing prevalence rates, certain regions, such as the Lake region, still face significant challenges. A multi-pronged approach, including bed nets, indoor residual spraying, effective medicines, and preventive measures for pregnant women, has contributed to the overall decline in malaria prevalence. Looking ahead, the timeline for the vaccine's approval and deployment is set for 2018, with preparations underway this year for the pilot phase. The assessment of safety and impact on child survival will continue through 2022. As World Malaria Day approaches, Kenya's involvement in the pilot of the new malaria vaccine offers hope in the ongoing battle against this deadly disease. The collaborative efforts between the government, international organizations, and health authorities signal a proactive approach to malaria control and prevention.